|
| |
Clinical Data's Cogenics Division Launches Services on
Roche 454 GS FLX
NEWTON, Mass. - June 7, 2007 - Clinical Data, Inc.
(NASDAQ: CLDA) announced today that its Cogenics division has successfully
launched the 454 Genome Sequencer FLX system (the "454 FLX system") at its
facility in Meylan, France, some eight weeks after the signing of the
co-marketing agreement with Roche Diagnostics Inc., to offer "next generation"
sequencing services. The system enhances Cogenics' portfolio of services by
providing whole genome sequencing, Expressed Sequence Tag sequencing,
identification of small RNAs, transcriptome analysis, and metagenomics on the
new platform.
"Our team is enthusiastic about the level of customer interest in the 454 FLX
system and pleased to be able to meet our customers' growing needs by providing
complete solutions for low-cost and high-efficiency sequencing programs," stated
Robert Bondaryk, Ph.D., Senior Vice President and General Manager of Cogenics.
"We have already attracted new customers for the first projects on the platform
and we have a strong pipeline of current and new customer interest in 454 FLX
sequencing as a companion to traditional automated Sanger sequencing."
"I am truly excited about the speed and professionalism with which our team
installed the 454 technology. This represents another example of Cogenics'
strong technical abilities and commitment to leveraging proven advances in
technology and quality for its clients," stated Drew Fromkin, Clinical Data's
President and CEO. "We feel that the platform's ability to deliver value to our
clients will translate into rapid, healthy returns for Cogenics."
Cogenics, together with its sister division PGxHealth, will be exhibiting at the
upcoming European Society for Human Genetics Conference, taking place in Nice,
France between June 16 - 19, 2007. Attendees will be most welcome to visit the
Clinical Data stand (no.570) to discuss Cogenics' services in more detail.
For more information about Cogenics' offering of the 454 FLX system, as well as
its other genomic resources and services, please contact Laure Turner, Product
Manager for Sequencing, at +1-314-303-9147, or Claire Vigneron, Cogenics'
European Marketing Manager, at + 33 (0)4 56 38 11 03. For more information about
Clinical Data, visit the company's website at
www.clda.com .
About Cogenics
Cogenics offers more than 18 years of experience as a trusted provider of
the broadest range of pharmacogenomics and molecular biology services available
globally. Cogenics provides integrated services for nucleic acid extraction,
genotyping, sequencing, QPCR, and gene expression, as well as serving as a
biorepository for both research and regulated environments: GLP, cGMP and CLIA.
Cogenics combines operations from the acquisitions of Genaissance
Pharmaceuticals, Lark Technologies (US & UK), Icoria, and Genome Express
(France). Its customers include some of the world's most respected
pharmaceutical and biotechnology companies, agencies of the US National
Institutes of Health, leading government and academic researchers in the
international life science community, and major agricultural companies and
agencies.
About Clinical Data, Inc.
Clinical Data, Inc. is a global biotechnology company unlocking the
potential of molecular discovery, from targeted science to better healthcare.
Its Cogenics division provides molecular biology and pharmacogenomics services
to pharmaceutical and biotech companies and academics institutions in both
research and regulated environments. Its PGxHealth division focuses on genetic
test and biomarker development to help predict drug safety and efficacy, thereby
reducing health care costs and improving clinical outcomes. Its Vital
Diagnostics division offers in vitro diagnostics solutions for the clinical
laboratory. Through these divisions, Clinical Data is leveraging advances in
molecular discovery to provide tangible benefits for patients, doctors,
scientists, and health plans worldwide.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995
This press release contains certain forward-looking information about Clinical
Data that is intended to be covered by the safe harbor for "forward-looking
statements" provided by the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not historical
facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)"
and similar expressions are intended to identify forward-looking statements.
These statements include, but are not limited to statements regarding: our
ability to successfully integrate the operations, business, technology and
intellectual property obtained in our acquisitions; our ability to obtain
regulatory approval for, and successfully introduce our products and services;
our ability to expand our long-term business opportunities; our ability to
maintain normal terms with our customers and partners; financial projections and
estimates and their underlying assumptions; and statements regarding future
performance. All of such statements are subject to certain risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of the Company, that could cause actual results to differ materially
from those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include, but are not
limited to: whether our sequencing services will gain wide acceptance in the
market; our ability to achieve the expected synergies and operating efficiencies
from all of our acquisitions; the strength of our intellectual property rights;
competition from pharmaceutical, biotechnology and diagnostics companies; the
development of and our ability to take advantage of the market for
pharmacogenetic products and services; general economic downturns; and other
risks contained in our various SEC reports and filings, including but not
limited to our Quarterly Report on Form 10-Q for the quarter ended December 31,
2006, and our subsequent Current Reports on Form 8-K filed with the Securities
and Exchange Commission. Readers are cautioned not to place undue reliance on
these forward-looking statements that speak only as of the date hereof, and we
do not undertake any obligation to revise and disseminate forward-looking
statements to reflect events or circumstances after the date hereof, or to
reflect the occurrence of or non-occurrence of any events.
--
For further information, please contact:
Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100
allo@ala.com /
neil@ala.com
| |
|
